Going-concern and liquidity risk
The company has recurring losses and depends on external capital and collaboration receipts to fund operations.
- Scope
- Development-stage operations and R&D spend
- Materiality
- high
Cue Biopharma, Inc.
Cue Biopharma is a clinical-stage biopharmaceutical company developing injectable precision immunotherapies designed to selectively modulate disease-relevant T cells. Its core Immuno-STAT platform is being applied to oncology and autoimmune disease, with most of the company’s activity still centered on research, development, and partnering rather than product sales.
−93,2 %
−96,9 %
+195,7 %
2.74
2.74
| % | |
|---|---|
| Clinical-stage immunotherapy programs | 70% Internal drug candidates in oncology and autoimmune disease, including CUE-101, CUE-102, CUE-401 and the CUE-500 series. |
| Collaborative research and license revenue | 30% Milestone, research, and license revenue from partnered programs such as BI, IMSCP, LG Chem, Ono, and Merck. |
Cue Biopharma does not sell approved drugs commercially; its current counterparties are pharmaceutical and...
- Strategic pharma partnersprimary
Large pharmaceutical companies that license or co-develop programs such as CUE-501 to access differentiated biology and share development risk.
- Biotechnology collaboratorsprimary
Smaller biotech partners that fund research, option rights, or regional development in exchange for access to the platform.
- Oncology patients and providersemerging
Future end users for CUE-101/CUE-102 if approved, especially in HPV+ head and neck cancer and other solid tumors.
- Autoimmune disease patientsemerging
Potential future users of CUE-401 and CUE-500 series therapies designed to restore immune balance.
Cue Biopharma is headquartered in the United States and conducts its core R&D there, while its business model depends...
- •Headquartered and primarily operated in the United States
- •R&D and clinical development are centered in the U.S.
- •Partner agreements can grant worldwide rights to collaborators
- •Global supply chain exposure includes China-based service providers
- •Future commercialization would likely be multi-region through partners
The company’s near-term strategy is to advance its most promising internal assets while using partnerships to extend...
01
Advance CUE-401 into the clinicshort-term
A new IND-stage autoimmune asset can refresh the pipeline and create a near-term value catalyst.
02
Secure and expand strategic collaborationsshort-term
Partnering reduces funding burden and helps validate the platform across oncology and autoimmune disease.
03
Broaden the pipeline from the Immuno-STAT platformmedium-term
A diversified pipeline lowers dependence on any single clinical outcome and increases partnering leverage.
Cue Biopharma remains a development-stage company with recurring losses and no commercial product revenue, so financing...
Clinical development failure
Pipeline value depends on positive efficacy, tolerability, and regulatory progress for candidates like CUE-101, CUE-102, and CUE-401.
- Scope
- Lead oncology and autoimmune programs
- Materiality
- high
Partner concentration and termination risk
Collaboration revenue is tied to a small number of agreements and can stop if partners terminate or slow work.
- Scope
- BI, IMSCP, LG Chem and prior Ono/Merck agreements
- Materiality
- high
Supply-chain and tariff disruption
Development and manufacturing may rely on external providers, including China-linked suppliers, which can be affected by trade restrictions.
- Scope
- CMOs, raw materials, clinical supply
- Materiality
- medium
Nasdaq listing compliance
Failure to maintain minimum bid price or other requirements could lead to delisting and reduced capital access.
- Scope
- Public equity financing
- Materiality
- medium
Collaboration revenue recognition
Affects reported revenue and comparability across quarters
Research and development expense recognition
Affects operating loss and makes asset-level profitability hard to assess
Going-concern assessment
Can influence disclosure, valuation, and investor perception
Contract liabilities and milestone estimates
Affects balance sheet obligations and revenue timing
: 28.4.2026